加载中
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
前收盘价
US$78.96
−US$5.02 · -5.98%
盘中时间采用ET。市场数据可能有所延迟。
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
日内区间
当前US$78.96
52周区间
当前US$78.96
盘中时间采用ET。市场数据可能有所延迟。
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
日内区间
当前US$78.96
52周区间
当前US$78.96
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 99.04亿 USD | 1300.6万 USD | 560.02万 USD | 759.16万 USD | 649.32万 USD |
| 销售、一般及管理费用 | 68亿 USD | 315.57万 USD | 323.1万 USD | 294.53万 USD | 263.4万 USD |
| 营业费用 | 1670.44万 USD | 1616.17万 USD | 883.12万 USD | 1053.69万 USD | 912.72万 USD |
| 利息收入 | 298.75万 USD | 40.4万 USD | 42.9万 USD | 2.12万 USD | 2.4万 USD |
| 营业利润 | −1670.44万 USD | −1616.17万 USD | −883.12万 USD | −1053.69万 USD | −912.72万 USD |
| 净利润 | −1371.69万 USD | −1558.64万 USD | −840.22万 USD | −1051.56万 USD | −910.32万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$126
上涨空间 59.57%价格历史记录不可用
最高：US$145平均的：US$126最低：US$105报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1788.48万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1168.43万0.12%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1020.94万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF511.11万0.01%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO290.32万0.02%180亿 USD0.06%US$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO169.9万0.08%19亿 USD0.13%US$230.11+1.02%
iShares Micro-Cap ETFIWC119.87万0.09%13.17亿 USD0.60%US$183+0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT97.92万0.00%980.88亿 USD0.03%US$169.66+0.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
